Ashland Inc. (ASH) recorded third-quarter fiscal 2024 (ended Jun 30, 2024) adjusted earnings of $1.49 per share, up from $1.23 in the prior-year quarter. The bottom line surpassed the Zacks Consensus Estimate of $1.47.Sales were down 0.4% year over year to $544 million. The top line missed the Zacks Consensus Estimate of $569 million. Higher volumes within the Personal Care and Specialty Additives segments were partly offset by reduced Life Sciences volumes. Pricing was weaker than the prior-year quarter.Se ...

For the quarter ended June 2024, Ashland (ASH) reported revenue of $544 million, down 0.4% over the same period last year. EPS came in at $1.49, compared to $1.23 in the year-ago quarter.The reported revenue represents a surprise of -4.40% over the Zacks Consensus Estimate of $569.02 million. With the consensus EPS estimate being $1.47, the EPS surprise was +1.36%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next ...

Ashland (ASH) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $1.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.36%. A quarter ago, it was expected that this chemical company would post earnings of $1.19 per share when it actually produced earnings of $1.27, delivering a surprise of 6.72%.Over the last four quarters, the company ha ...

Exhibit 99.1 Ashland reports financial results1for third quarter fiscal 2024, issues outlook for fourth quarter and full-year fiscal 2024 • Sales of $544 million • Net income (including discontinued operations) of $6 million, or $0.12 per diluted share • Income from continuing operations of $31 million, or $0.60 per diluted share • Adjusted income from continuing operations excluding intangibles amortization expense of $75 million, or $1.49 per diluted share • Adjusted EBITDA of $139 million, up five percen ...

Sales of $544 millionNet income (including discontinued operations) of $6 million, or $0.12 per diluted shareIncome from continuing operations of $31 million, or $0.60 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $75 million, or $1.49 per diluted shareAdjusted EBITDA of $139 million, up five percent from the prior-year quarterCash flows provided by operating activities of $128 million; ongoing free cash flow2 of $112 millionRepurchased 1.3 million ...

Sales of $544 millionNet income (including discontinued operations) of $6 million, or $0.12 per diluted shareIncome from continuing operations of $31 million, or $0.60 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $75 million, or $1.49 per diluted shareAdjusted EBITDA of $139 million, up five percent from the prior-year quarterCash flows provided by operating activities of $128 million; ongoing free cash flow2 of $112 millionRepurchased 1.3 million ...

Investors might want to bet on Ashland (ASH) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a cha ...

Investors interested in stocks from the Chemical - Specialty sector have probably already heard of Ashland (ASH) and Novozymes A/S (NVZMY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy tha ...

Investors looking for stocks in the Chemical - Specialty sector might want to consider either Ashland (ASH) or Novozymes A/S (NVZMY) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes compa ...

Investors interested in Basic Materials stocks should always be looking to find the best-performing companies in the group. Has Aris Mining Corporation (ARMN) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.Aris Mining Corporation is one of 238 individual stocks in the Basic Materials sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to ...